Cover Image
市場調查報告書

免疫檢查點抑制劑市場預測

Immune Checkpoint Inhibitors Market (2nd Edition), 2015 - 2025

出版商 ROOTS ANALYSIS 商品編碼 318569
出版日期 內容資訊 英文 401 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
免疫檢查點抑制劑市場預測 Immune Checkpoint Inhibitors Market (2nd Edition), 2015 - 2025
出版日期: 2015年07月20日 內容資訊: 英文 401 Pages
簡介

本報告提供免疫檢查點抑制劑的市場相關調查、癌症治療藥與癌症免疫概要、癌症治療的機制與藥物類別、主要的抑制劑的作用機制、開發平台趨勢、已上市的3種藥物的開發過程、銷售額預測、主要的各適應症的競爭趨勢、企業間的各種契約與聯盟、主要經營者簡介等彙整資料。

第1章 序文

第2章 摘要整理

第3章 癌症治療藥和癌症免疫

  • 概要
  • 癌症治療的4個支柱
  • 免疫療法:強力的地盤
  • 癌症免疫(癌症免疫療法)
  • 癌症免疫療法的分類
    • 各機制
    • 各類藥物
      • 單株抗體 (mAbs)
      • 細胞激素
      • 細胞治療
      • 免疫檢查點抑制劑

第4章 目前市場環境

  • 調查範圍、觀察
    • 免疫檢查點抑制劑的共同標的
  • 已通過核準的3種免疫檢查點抑制劑
  • 免疫檢查點抑制劑:臨床、前臨床開發平台
    • Bristol Myers Squibb主導的免疫檢查點抑制劑市場
    • 各公司評價多種檢查點標的
  • 開發最後階段的4種藥物
  • 企業評價各種分子類型:從單株抗體到融合蛋白品質
  • 綜合性的未來展望:銷售額預測
    • 調查範圍與預測手法
    • 整體市場規模與預測

第5章 CTLA-4抑制劑:重要分子和未來展望

  • 作用機制
  • 免疫檢查點抑制劑市場先鋒
  • 開發平台分析
    • 開發平台中的有限的分子
    • 進行融合蛋白品質開發的KAHR Medical
  • Yervoy (Bristol Myers Squibb)
    • 簡介
    • 開發的過程
    • 劑型和生產
    • 治療成本與回本
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 銷售情況
    • 專利的失效
    • 聯盟
    • 銷售額預測
  • Tremelimumab (MedImmune)
    • 簡介
    • 開發的過程
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 目標人群
    • 未來的計劃
    • 銷售額預測
  • CTLA-4抑制劑:Roots Analysis的展望

第6章 PD-1、PD-L1抑制劑:重要分子和未來展望

  • 作用機制
  • 最近的2種類型的市場投入強化市場氣氛
    • PD-1 / PD-L1抑制劑開發平台分析
    • 吸引大廠、小規模雙方製藥經營者的市場
    • 大部分的候補藥在開發初期階段等
  • Opdivo (Bristol Myers Squibb)
    • 簡介
    • 開發的過程
    • 劑型和生產
    • 治療成本與回本
    • 專利的失效
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 聯盟
    • 銷售額預測
  • Keytruda (Merck)
    • 簡介
    • 劑型和生產
    • 專利的失效
    • 治療成本與回本
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 聯盟
    • 銷售額預測
  • MPDL3280A (Roche)
    • 簡介
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 聯盟
    • 銷售額預測
  • MEDI4736 (MedImmune)
    • 簡介
    • 現狀與發展情形
    • 搭配診斷的開發
    • 主要臨床實驗的結果
    • 聯盟
    • 銷售額預測
  • PD-1、PD-L1抑制劑:Roots Analysis的展望

第7章 新的免疫檢查點抑制劑:重要分子和未來展望

  • 新的免疫檢查點需求的劇增
  • IDO抑制劑:最受歡迎的開發中藥物類別
  • 小規模製藥公司壟斷新的檢查點部門
  • Elotuzumab:開發最後階段的唯一藥物
  • Elotuzumab (Bristol Myers Squibb)
    • 簡介
    • 開發的過程
    • 作用機制
    • 專利資訊
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 聯盟
    • 未來的計劃
    • 銷售額預測
  • INCB024360 (Incyte Corporation)
    • 簡介
    • 專利資訊
    • 製造
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 聯盟
  • Indoximod (NewLink Genetics)
    • 簡介
    • 製造
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 專利資訊
    • 聯盟
    • 未來的計劃
  • Lirilumab (Bristol Myers Squibb)
    • 簡介
    • 作用機制
    • 現狀與發展情形
    • 主要臨床實驗的結果
    • 聯盟
    • 未來的計劃
  • 新的檢查點抑制劑:Roots Analysis的展望

第8章 主要適應症的競爭

  • 概要
  • 黑色素瘤
  • 惡性間皮癌市場
  • NSCLC市場
  • 多發骨髓瘤市場
  • 卵巢癌市場
  • 膀胱癌市場

第9章 契約、聯盟

  • 本章概要
  • 一般臨床試驗的聯盟
  • 擴大開發平台的大醫藥品經營者的收購
  • 共同開發、市售化取向的契約
  • 產品授權合約
  • 有效並用治療的臨床試驗的聯盟
  • 醫藥品受託製造的契約
  • 研究的聯盟

第10章 企業簡介

  • 本章概要
  • Bristol Myer Squibb
  • AstraZeneca
  • Merck & Co.
  • Roche / Genentech
  • Incyte Corporation
  • NewLink Genetics
  • 其他
    • arGEN-X
    • Seattle Genetics
    • Pfizer
    • MacroGenics
    • Celldex Therapeutics
    • CureTech
    • Immutep
    • Innate Pharma
    • Sorrento Therapeutics
    • GlaxoSmithKline
    • GITR, Inc.

第11章 總論

  • 免疫檢查點抑制劑:對癌症患者而言的新希望
  • 目前旗手:PD-1、PD-L1
  • 積極聯盟是未來成功的關鍵
  • 開發平台有數種重量級產品,整體的市場機會很大
  • 結束

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10043

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). Interest has surged in other classes of immunotherapeutics; these include Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and many under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

In addition to the marketed drugs (Yervoy, Opdivo and Keytruda), we expect a number of drugs currently in advanced stages of development (Tremelimumab, Elotuzumab, RG7446 and Avelumab)to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

Synopsis

The "Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025 " report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the study is to review the prospects laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst other elements, the report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
  • Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations
  • Combinationtherapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies
  • Various investments and grants received by the companies focused in this area
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2015. The report provides the market forecast for the period 2015-2025, respectively. The research, analysis and insights presented in this report include potential sales of several Immune Checkpoint Inhibitors; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1.The industry is characterized by the presence of three marketed drugs and 34 drugs in clinical development for oncological indications. The marketed and clinical pipeline includes two CTLA-4, nine PD-1 / PD-L1 and 26 novel Immune Checkpoint Inhibitors.The dynamic pipeline also includes several molecules in preclinical/ discovery stage; in our research, we identified about 70 such molecules.
  • 2.BMS, with tenImmune Checkpoint Inhibitors (marketed / under development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck & Co, Pfizer, Merck KGaA, Roche, GSK, Novartis and Amgen.
  • 3.Many start-ups, small companies and university spin-offs have also emerged in the past two years. Examples (in alphabetical order) include Agenus, Alligator Bioscience, Ambrx, AnaptysBio, arGEN-X, Bioceros, BioNovion, Cellerant Therapeutics, Checkpoint Therapeutics, Compugen, CureTech, Enumeral, Five Prime Therapeutics, Genmab, GITR, ImmuNext, IOmet Pharma, iTeos Therapeutics, Jounce Therapeutics, KAHR Medical, Multimeric Biotherapeutics, Nativis, Orega Biotech, Pelican Therapeutics, Pieris Pharmaceuticals, Prima BioMed, Redx Pharma, Sorrento Therapeutics,Tesaro, TG Therapeutics, Theravectys and ToleroTech.
  • 4.Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have gained maximum attention; this is followed by molecules targeting LAG-3, CD-70, OX-40 and CD-40. Although Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market.
  • 5.Collaborations have helped the market reach its current growth trajectory.Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; the period Jan 2014-May 2015 saw over 40 such collaborations for a number of molecules.
  • 6.We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2015 - 2025, our forecast suggests that the market will witness an annualized growth rate of 27.7%.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outline

Chapter 2 presents an executive summary of the report. It offers a high level view on where the Immune Checkpoint Inhibitors market is headed in the mid-long term.

Chapter 3 provides a general introduction to Immune Checkpoint Inhibitors. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and, specifically, the emergence of Immune Checkpoint Inhibitors.

Chapter 4 provides a comprehensive landscape of the Immune Checkpoint Inhibitors market. This chapter includes information on more than 100 inhibitors which are currently in different stages of development (both clinical and pre-clinical / discovery). The detailed analysis of this development pipeline includes information on types of molecules, most commonly targeted indications, current phases of development and the likely launch timelines.

Chapter 5 focuses on CTLA-4 inhibitors and presents the current scenario and the future outlook for this specific class of molecules. The chapter includes detailed drug profiles of the marketed and drugs under development. We have presented information on several parameters such as history of development, clinical trial results, manufacturing, cost and reimbursement. It includes the likely sales forecast of the drugs currently in advanced stage of development.

Chapter 6 focuses on PD-1 and PD-L1 inhibitors and presents the current scenario and the future outlook for this specific class of inhibitors. As with the CTLA-4 inhibitors, this chapter provides a holistic view on the various drugs belonging to this class and their future sales potential.

Chapter 7 focuses on novel inhibitors. Examples of these inhibitors include IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP and ICOS. As in the earlier two chapters, we have provided detailed drug profiles and the future outlook for these new set of inhibitors.

Chapter 8 provides details on all the active/planned clinical studies evaluating Phase II/III/marketed Immune Checkpoint Inhibitors as combination therapies. The chapter focuses on the most common combinations, provides adetailed analysis of all the listed clinical studies and highlights the evolving preference of pharma companies in terms of differing combination classes.

Chapter 9 offers a comprehensive competitive landscape of various therapies being used for the treatment of certain oncological indications; these indications have been the prime focus of companies developing Immune Checkpoint Inhibitors.

Chapter 10 includes an elaborate discussion on the various collaborations and partnerships which have been forged amongst the players in the market over the last several years.

Chapter 11 presents details on the various investments and grants received by the companies focused in the area of Immune Checkpoint Inhibitors. The analysis highlights the growing interest from the VC community and other strategic investors.

Chapter 12 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline drugs and recent collaborations and developments.

Chapter 13 is a collection of transcripts of interviews conducted during the course of this study.

Chapter 14 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 provides the list of companies mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Cancer Therapeutics and Immuno-Oncology

  • 3.1. Chapter Overview
  • 3.2. The Four Pillars of Cancer Therapy
  • 3.3. Immunotherapy: Gaining A Strong Foothold
    • 3.3.1. Activation and Suppression Immunotherapies
  • 3.4. Immuno-Oncology (Cancer Immunotherapy)
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
    • 3.5.2. By Product Class
      • 3.5.2.1. Monoclonal Antibodies (mAbs)
      • 3.5.2.2. Cytokines
      • 3.5.2.3. Cell Based Therapies
      • 3.5.2.4. Immune Checkpoint Inhibitors

4. Current Market Landscape

  • 4.1. Scope and Observations
  • 4.2. Common Targets for Immune Checkpoint Inhibitors
  • 4.3. Three Approved Immune Checkpoint Inhibitors in Market
  • 4.4. Immune Checkpoint Inhibitors: Clinical and Preclinical Pipeline
    • 4.4.1. Immune Checkpoint Inhibitors: Distribution by Drug Developers
    • 4.4.2. Immune Checkpoint Inhibitors: Distribution by Targets
    • 4.4.3. Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
    • 4.4.4. Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • 4.5. Overall Future Outlook: Sales Forecast, 2015 - 2025
    • 4.5.1. Scope and Forecast Methodology
    • 4.5.2. Overall Market Size and Forecast

5. CTLA-4 Inhibitors: Key Molecules and Future Outlook

  • 5.1. CTLA-4 Inhibitors: Mechanism of Action
  • 5.2. Pioneers of Immune Checkpoint Inhibitors Market
  • 5.3. CTLA-4 Inhibitors: Pipeline Analysis
    • 5.3.1. CTLA-4 Inhibitors: Distribution by Highest Phase of Development
    • 5.3.2. CTLA-4 Inhibitors: Distribution by Type of Molecule
  • 5.4. Yervoy / Ipilimumab (Bristol Myers Squibb)
    • 5.4.1. Introduction
    • 5.4.2. History of Development
    • 5.4.3. Dosage and Manufacturing
    • 5.4.4. Treatment Cost and Reimbursement
    • 5.4.5. Current Status of Development
    • 5.4.6. Key Clinical Trial Results
    • 5.4.7. Historical Sales
    • 5.4.8. Patent Expiry
    • 5.4.9. Collaborations
    • 5.4.10. Target Patient Population
    • 5.4.11. Yervoy/ Ipilimumab Sales Forecast, 2015 - 2025
  • 5.5. Tremelimumab (MedImmune)
    • 5.5.1. Introduction
    • 5.5.2. History of Development
    • 5.5.3. Current Status of Development
    • 5.5.4. Key Clinical Trial Results
    • 5.5.5. Collaborations
    • 5.5.6. Target Patient Population
    • 5.5.7. Tremelimumab Sales Forecast, 2015 - 2025
  • 5.6. CTLA-4 Inhibitors: Roots Analysis' Perspective

6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook

  • 6.1. PD-1/PD-L1 Inhibitors: Mechanism of Action
  • 6.2. Two Recent Launches Have Strengthened the Market Sentiment
  • 6.3. PD-1 / PD-L1 Inhibitors: Pipeline Analysis
    • 6.3.1. PD-1 / PD-L1 Inhibitors: Landscape Analysis
    • 6.3.2. PD-1 / PD-L1 Inhibitors: Distribution by Target
    • 6.3.3. PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
    • 6.3.4. PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule
  • 6.4. Opdivo/Nivolumab (Bristol Myers Squibb)
    • 6.4.1. Introduction
    • 6.4.2. History of Development
    • 6.4.3. Dosage and Manufacturing
    • 6.4.4. Treatment Cost and Reimbursement
    • 6.4.5. Current Status of Development
    • 6.4.6. Key Clinical Trial Results
      • 6.4.6.1. Metastatic Melanoma (Single Agent)
      • 6.4.6.2. NSCLC
      • 6.4.6.3. Advanced Melanoma (Combination Therapy)
      • 6.4.6.4. Hodgkin Lymphoma
      • 6.4.6.5. RCC
      • 6.4.6.6. Hepatocellular Carcinoma
    • 6.4.7. Historical Sales
    • 6.4.8. Patent Expiry
    • 6.4.9. Collaborations
    • 6.4.10. Target Patient Population
    • 6.4.11. Opdivo /Nivolumab Sales Forecast, 2015 - 2025
  • 6.5. Keytruda / Pembrolizumab (Merck)
    • 6.5.1. Introduction
    • 6.5.2. History of Development
    • 6.5.3. Dosage and Manufacturing
    • 6.5.4. Treatment Cost and Reimbursement
    • 6.5.5. Current Status of Development
    • 6.5.6. Key Clinical Trial Results
      • 6.5.8.1. Advanced Melanoma
      • 6.5.8.2. NSCLC
      • 6.5.8.3. Advanced Solid Tumors
      • 6.5.8.4. Hodgkin Lymphoma
      • 6.5.8.5. Advanced Head and Neck Cancer
      • 6.5.8.6. Advanced Bladder Cancer
      • 6.5.8.7. Advanced Gastric Cancer
      • 6.5.8.8. Metastatic Breast Cancer
    • 6.5.7. Historical Sales
    • 6.5.8. Patent Expiry
    • 6.5.9. Collaborations
    • 6.5.10. Target Patient Population
    • 6.5.11. Keytruda / Pembrolizumab Sales Forecast, 2015 - 2025
  • 6.6. MPDL3280A/RG7446 (Roche)
    • 6.6.1. Introduction
    • 6.6.2. History of Development
    • 6.6.3. Current Status of Development
    • 6.6.4. Key Clinical Trial Results
      • 6.6.4.1. NSCLC
      • 6.6.4.2. Metastatic Bladder Cancer
      • 6.6.4.3. Metastatic Breast Cancer
      • 6.6.4.4. Metastatic Renal Cell Carcinoma
    • 6.6.5. Collaborations
    • 6.6.6. Target Patient Population
    • 6.6.7. MPDL3280A/RG7446 Sales Forecast, 2015 - 2025
  • 6.7. MEDI4736 (MedImmune)
    • 6.7.1. Introduction
    • 6.7.2. Current Status of Development
    • 6.7.3. Key Clinical Trial Results
    • 6.7.4. Collaborations
    • 6.7.5. Target Patient Population
    • 6.7.6. MEDI4736 Sales Forecast, 2015 - 2025
  • 6.8. Avelumab/MSB0010718C (Merck KGaA/Pfizer)
    • 6.8.1. Introduction
    • 6.8.2. Current Status of Development
    • 6.8.3. Key Clinical Trial Results
    • 6.8.4. Collaborations
    • 6.8.5. Target Patient Population
    • 6.8.6. Avelumab /MSB0010718C Sales Forecast, 2015-2025
  • 6.9. Pidilizumab/ CT-011 (CureTech)
    • 6.9.1. Introduction
    • 6.9.2. Current Status of Development
    • 6.9.3. Key Clinical Trial Results
      • 6.9.3.1. Metastatic Melanoma
      • 6.9.3.2. B-cell Lymphoma
      • 6.9.3.3. Relapsed Follicular Lymphoma
    • 6.9.4. Target Patient Population
    • 6.9.5. Collaborations
  • 6.10. PD -1 and PD- L1 Inhibitors: Roots Analysis' Perspective

7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook

  • 7.1. Rush for the Novel Immune Checkpoints
  • 7.2. Novel Immune Checkpoint Inhibitors: Pipeline Analysis
    • 7.2.1. Novel Immune Checkpoint Inhibitors: Distribution by Target
    • 7.2.2. Novel Immune Checkpoint Inhibitors: Distribution by Companies
    • 7.2.3. Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
    • 7.2.4. Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • 7.3. Elotuzumab (Bristol Myers Squibb/AbbVie)
    • 7.3.1. Introduction
    • 7.3.2. Mechanism of Action
    • 7.3.3. History of Development
    • 7.3.4. Current Status of Development
    • 7.3.5. Key Clinical Trial Results
    • 7.3.6. Collaborations
    • 7.3.7. Target Patient Population
    • 7.3.8. Elotuzumab Sales Forecast, 2015- 2025
  • 7.4. Epacadostat/INCB024360 (Incyte Corporation)
    • 7.4.1. Introduction
    • 7.4.2. Mechanism of Action
    • 7.4.3. Manufacturing
    • 7.4.4. Current Status of Development
    • 7.4.5. Key Clinical Trial Results
    • 7.4.6. Target Patient Population
    • 7.4.7. Collaborations
  • 7.5. Indoximod (NewLink Genetics)
    • 7.5.1. Introduction
    • 7.5.2. Mechanism of Action
    • 7.5.3. Manufacturing
    • 7.5.4. Current Status of Development
    • 7.5.5. Key Clinical Trial Results
    • 7.5.6. Patent Information
    • 7.5.7. Target Patient Population
    • 7.5.8. Collaborations
  • 7.6. Lirilumab (Bristol Myers Squibb)
    • 7.6.1. Introduction
    • 7.6.2. Mechanism of Action
    • 7.6.3. Current Status of Development
    • 7.6.4. Key Clinical Trial Results
    • 7.6.5. Target Patient Population
    • 7.6.6. Collaborations
  • 7.7. IPH2201 (Innate Pharma)
    • 7.7.1. Introduction
    • 7.7.2. Mechanism of Action
    • 7.7.3. Current Status of Development
    • 7.7.4. Key Clinical Trial Results
    • 7.7.5. Target Patient Population
    • 7.7.6. Collaborations
  • 7.8. Novel Checkpoint Inhibitors: Roots Analysis' Perspective

8. Immune Checkpoint Inhibitors as Combination Therapy

  • 8.1. Introduction
  • 8.2. Combination Therapy: History of Development
  • 8.3. FDA approved Combination Therapies in Oncology
  • 8.4. Combination Therapies: FDA Guidelines
    • 8.4.1. Combinations of Previously Marketed Drugs or Biologics
    • 8.4.2. Combinations of Previously Marketed Drugs or Biologics with New Molecular Entities
    • 8.4.3. Combinations of New Molecular Entities with New Molecular Entities
  • 8.5. Combination Therapies: Immune Checkpoint Inhibitors
    • 8.5.1. Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
    • 8.5.2. Immune Checkpoint Inhibitors Combination Therapy Clinical Studies
      • 8.5.2.1. Distribution by Highest Phase of Development
      • 8.5.2.2. Distribution by Status
      • 8.5.2.3. Distribution by Type of Immune Checkpoint Inhibitor
      • 8.5.2.4. Distribution by Type of Combination Class
  • 8.6. Combination of Immune Checkpoint Inhibitors with Immune Checkpoint Inhibitors
  • 8.7. Combination of Immune Checkpoint Inhibitors with Chemotherapy
  • 8.8. Combination of Immune Checkpoint Inhibitors with Kinase Inhibitors
  • 8.9. Combination of Immune Checkpoint Inhibitors with Angiogenesis Inhibitors
  • 8.10. Combination of Immune Checkpoint Inhibitors with Cancer Vaccine
  • 8.11. Combination of Immune Checkpoint Inhibitors with Cytokines
  • 8.12. Combination of Immune Checkpoint Inhibitors with Radiotherapy
  • 8.13. Combination of Immune Checkpoint Inhibitors with Surgery
  • 8.14. Combination of Immune Checkpoint Inhibitors with Oncolytic Virus Immunotherapy
  • 8.15. Combination of Immune Checkpoint Inhibitors with Cell Based Immunotherapy
  • 8.16. Combination of Immune Checkpoint Inhibitors with Hormone Therapy
  • 8.17. Combination of Immune Checkpoint Inhibitors with Other Drug Classes

9. Competition in Key Indication Areas

  • 9.1. Chapter Overview
  • 9.2. Competition in Melanoma Market
  • 9.3. Competition in Malignant Mesothelioma Market
  • 9.4. Competition in NSCLC Market
  • 9.5. Competition in Multiple Myeloma Market
  • 9.6. Competition in Ovarian Cancer Market
  • 9.7. Competition in Bladder Cancer Market
  • 9.8. Competition in Kidney Cancer Market

10. Deals and Partnerships

  • 10.1. Chapter Overview
  • 10.2. Collaborations Inked in Immune Checkpoint Inhibitors Market
    • 10.2.1. Distribution by Type
    • 10.2.2. Distribution by Year of Partnership
  • 10.3. Large Pharmaceutical Companies Acquiring to Expand Pipelines
  • 10.4. Co-development and/or Commercialization Agreements
  • 10.5. Product Licensing Agreements
  • 10.6. Clinical Trial Collaborations to Validate Combination Therapies
    • 10.6.1. Clinical Trial Collaborations: Distribution by Target
    • 10.6.2. BMS and Merck Have Been the Most Active In Forging Clinical Trial Collaborations
  • 10.7. Contract Manufacturing Agreement
  • 10.8. Research Collaborations

11. Venture Capital Support

  • 11.1. Chapter Overview
  • 11.2. Instances of Investments / Grants in Immune Checkpoint Inhibitors Market
  • 11.3. Growing Venture Capitalist Interest
  • 11.4. Distribution of the Funding Instances on the Basis of Type of Funding
  • 11.5. Distribution by Total Amount of Investment in a Category

12. Company Profiles

  • 12.1. Chapter Overview
  • 12.2. Bristol Myer Squibb
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.2.4. Collaborations
  • 12.3. Merck & Co.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.3.4. Collaborations
  • 12.4. AstraZeneca
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.4.4. Collaborations
  • 12.5. Roche / Genentech
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.5.4. Collaborations
  • 12.6. Pfizer
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.6.4. Collaborations
  • 12.7. Incyte Corporation
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.7.4. Collaborations
  • 12.8. NewLink Genetics
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.8.4. Collaborations
  • 12.9. Innate Pharma
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.9.4. Collaborations
  • 12.10. CureTech
    • 12.10.1. Company Overview
    • 12.10.2. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.10.3. Collaborations
  • 12.11. Celldex Therapeutics
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.11.4. Collaborations
  • 12.12. arGEN-X
    • 12.12.1. Company Overview
    • 12.12.2. Technology Platforms
    • 12.12.3. Financial Performance
    • 12.12.4. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.12.5. Collaborations
  • 12.13. Seattle Genetics
    • 12.13.1. Company Overview
    • 12.13.2. Technology Platforms
    • 12.13.3. Financial Performance
    • 12.13.4. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.13.5. Collaborations
  • 12.14. MacroGenics
    • 12.14.1. Company Overview
    • 12.14.2. Technology Platforms
    • 12.14.3. Financial Performance
    • 12.14.4. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.14.5. Collaborations
  • 12.15. GlaxoSmithKline
    • 12.15.1. Company Overview
    • 12.15.2. Financial Performance
    • 12.15.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.15.4. Collaborations
  • 12.16. GITR, Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.16.3. Collaborations
  • 12.17. Agenus
    • 12.17.1. Company Overview
    • 12.17.2. Financial Performance
    • 12.17.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.17.4. Collaborations
  • 12.18. Compugen
    • 12.18.1. Company Overview
    • 12.18.2. Financial Performance
    • 12.18.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.18.4. Collaborations
  • 12.19. Tesaro
    • 12.19.1. Company Overview
    • 12.19.2. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.19.3. Collaborations
  • 12.20. BioNovion
    • 12.20.1. Company Overview
    • 12.20.2. Technology Platform
    • 12.20.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.20.4. Collaborations
  • 12.21. IOmet Pharma
    • 12.21.1. Company Overview
    • 12.21.2. Immune Checkpoint Inhibitors Pipeline, 2015
  • 12.22. Enumeral Biomedical Holdings
    • 12.22.1. Company Overview
    • 12.22.2. Technology Platform
    • 12.22.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.22.4. Financial Performance
    • 12.22.5. Collaborations
  • 12.23 Immutep (PrimaBioMed)
    • 12.23.1. Company Overview
    • 12.23.2. Technology Platform
    • 12.23.3. Immune Checkpoint Inhibitors Pipeline, 2015
    • 12.23.4. Collaborations

13. Conclusion

  • 13.1. Immune Checkpoint Inhibitors: A New Hope For Cancer Patients
  • 13.2. Current Flag Bearers: PD-1 and PD-L1
  • 13.3. Active Collaborations Likely To Be The Key To Future Success
  • 13.4. With Several Blockbusters In The Pipeline, The Overall Opportunity Is Huge
  • 13.5. Concluding Remarks

14. Interview Transcripts

15. Appendix: Tabulated Data

16. Appendix: List of Companies and Organizations

List of Figures

  • Figure 3.1 The Four Pillars of Cancer Therapy
  • Figure 3.2 Passive and Active Cancer Immunotherapies
  • Figure 4.1 Immune Checkpoint Inhibitors: Distribution by Drug Developers
  • Figure 4.2 Immune Checkpoint Inhibitors: Distribution by Targets
  • Figure 4.3 Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
  • Figure 4.4 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Figure 4.5 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 5.1 CTLA-4 Inhibitors: Distribution by Highest Phase of Development
  • Figure 5.2 CTLA-4 Inhibitors: Distribution by Type of Molecule
  • Figure 5.3 Yervoy / Ipilimumab Sales, 2011 - 2014 (USD Million)
  • Figure 5.4 Yervoy / Ipilimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 5.5 Tremelimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 5.6 CTLA-4 Inhibitors: Drivers and Restraints
  • Figure 6.1 PD-1 / PD-L1 Inhibitors: Distribution by Drug Developer
  • Figure 6.2 PD-1 / PD-L1 Inhibitors: Distribution by Target
  • Figure 6.3 PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
  • Figure 6.4 PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule
  • Figure 6.5 Opdivo / Nivolumab Sales, 2014- Q1 2015 (USD Million)
  • Figure 6.6 Opdivo / Nivolumab Sales Forecast, 2015-2025: Base Scenario (USD Million)
  • Figure 6.7 Keytruda / Pembrolizumab Sales, 2014 - Q1 2015(USD Million)
  • Figure 6.8 Keytruda / Pembrolizumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 6.9 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 6.10 MEDI4736 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 6.11 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 6.12 PD-1 and PD-L1 Inhibitors: Drivers and Restraints
  • Figure 7.1 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
  • Figure 7.2 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
  • Figure 7.3 Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
  • Figure 7.4 Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Figure 7.5 Elotuzumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 7.6 Novel Immune Checkpoint Inhibitors: Drivers and Restraints
  • Figure 8.1 Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
  • Figure 8.2 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
  • Figure 8.3 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Status
  • Figure 8.4 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Immune Checkpoint Inhibitor
  • Figure 8.5 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Combination Class
  • Figure 10.1 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
  • Figure 10.2 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
  • Figure 10.3 Clinical Trial Collaborations: Distribution by Target
  • Figure 11.1 Immune Checkpoint Inhibitors Funding Instances: Cumulative Investments by Year, 2001-2015
  • Figure 11.2 Immune Checkpoint Inhibitors Funding Instances: Distribution by Categories
  • Figure 11.3 Immune Checkpoint Inhibitors Funding Instances: Distribution by Amount Invested in a Category (USD Million)
  • Figure 12.1 BMS Revenues, 2011 - Q1 2015 (USD Billion)
  • Figure 12.2 BMS Revenues: Distribution by Therapeutic Areas, 2013 - 2014 (USD Million)
  • Figure 12.3 Merck Revenues, 2009 - Q1 2015 (USD Million)
  • Figure 12.4 Merck Revenues: Distribution by Business Segment, 2014 (USD Billion)
  • Figure 12.5 AstraZeneca Revenues, 2009 - Q1 2015(USD Million)
  • Figure 12.6 AstraZeneca Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
  • Figure 12.7 Roche Revenues, 2009-Q1 2015 (CHF Billion)
  • Figure 12.8 Roche Revenues: Distribution by Business Segments, 2012 - 2014 (CHF Billion)
  • Figure 12.9 Roche Pharmaceutical Revenues: Distribution by Therapeutic Areas, 2014 (CHF Billion)
  • Figure12.10 Pfizer Revenues, 2011 - Q1 2015 (USD Billion)
  • Figure 12.11 Pfizer Revenues: Distribution by Business Segments, 2014 (USD Million)
  • Figure 12.12 Pfizer Revenues: Distribution by Therapeutic Areas, 2013 - 2014, (USD '000)
  • Figure 12.13 Incyte Corporation Revenues, 2011 - Q1 2015 (USD Million)
  • Figure 12.14 NewLink Genetics Revenues, 2011 - Q1 2015 (USD Million)
  • Figure 12.15 Innate Pharma Revenues, 2011 - Q1 2015 (EUR Million)
  • Figure 12.16 Celldex Therapeutics Revenues, 2011 - Q1 2015 (USD Million)
  • Figure 12.17 Seattle Genetics Revenues, 2011 - Q1 2015 (USD Million)
  • Figure 12.18 MacroGenics Revenues, 2011 - Q1 2015 (USD Million)
  • Figure12.19 GSK Revenues, 2009 - Q1 2015 (GBP Billion)
  • Figure12.20 GSK Pharmaceutical and Vaccine Revenues: Distribution by Business Domains 2014, (GBP Billion)
  • Figure12.21 Compugen Revenues, 2012 - Q1 2015 (USD Million)
  • Figure 12.22 Enumeral Revenues, 2013 - Q1 2015 (USD '000)
  • Figure 13.1 Immune Checkpoint Inhibitors Market (USD Billion), 2015, 2020 and 2025

List of Tables

  • Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
  • Table 4.1 Co-Stimulatory Molecules as Target for Immune Checkpoint Inhibition
  • Table 4.2 Immune Checkpoint Inhibitors: Marketed and Clinical Pipeline, 2015
  • Table 4.3 Immune Checkpoint Inhibitors: Preclinical and Discovery Pipeline, 2015
  • Table 4.4 Immune Checkpoint Inhibitors: Current Development Phase and Expected Launch Year of Drugs
  • Table 5.1 Pipeline of CTLA-4 Inhibitors, 2015
  • Table 5.2 Yervoy /Ipilimumab: History of Development
  • Table 5.3 Yervoy /Ipilimumab: Dosage and Packaging
  • Table 5.4 Yervoy /Ipilimumab: Current Status of Development
  • Table 5.5 Tremelimumab: Current Status of Development
  • Table 6.1 Pipeline of PD-1 and PD-L1 Inhibitors, 2015
  • Table 6.2 PD-1 / PD-L1 Inhibitors: Landscape Analysis
  • Table 6.3 Opdivo/Nivolumab: Dosage and Packaging
  • Table 6.4 Opdivo/Nivolumab: Current Status of Development
  • Table 6.5 Keytruda / Pembrolizumab: Current Status of Development
  • Table 6.6 MPDL3280A / RG7446: Current Status of Development
  • Table 6.7 MEDI4736: Current Status of Development
  • Table 6.8 Avelumab / MSB0010718C: Current Status of Development
  • Table 6.9 Pidilizumab / CT-011: Current Status of Development
  • Table 6.10 Pidilizumab / CT-011: Investigator Sponsored Clinical Studies
  • Table 7.1 Pipeline of Novel Immune Checkpoint Inhibitors, 2015
  • Table 7.2 Elotuzumab: Current Status of Development
  • Table 7.3 Epacadostat / INCB024360: Current Status of Development
  • Table 7.4 Indoximod: Current Status of Development
  • Table 7.5 NewLink Genetics: Patent Portfolio Related to IDO Inhibitors
  • Table 7.6 Lirilumab: Current Status of Development
  • Table 8.1 FDA Approved Combination Therapies in Oncology, 2001-2015
  • Table 8.2 Combination of Immune Checkpoint Inhibitors with Immune Checkpoint Inhibitors
  • Table 8.3 Combination of Immune Checkpoint Inhibitors with Chemotherapy
  • Table 8.4 Combination of Immune Checkpoint Inhibitors with Kinase Inhibitors
  • Table 8.5 Combination of Immune Checkpoint Inhibitors with Chemotherapy
  • Table 8.6 Combination of Immune Checkpoint Inhibitors with Cancer Vaccine
  • Table 8.7 Combination of Immune Checkpoint Inhibitors with Cytokines
  • Table 8.8 Combination of Immune Checkpoint Inhibitors with Radiotherapy
  • Table 8.9 Combination of Immune Checkpoint Inhibitors with Surgery
  • Table 8.10 Combination of Immune Checkpoint Inhibitors with Oncolytic Virus Immunotherapy
  • Table 8.11 Combination of Immune Checkpoint Inhibitors with Cell Based Immunotherapy
  • Table 8.12 Combination of Immune Checkpoint Inhibitors with Hormone Therapy
  • Table 8.13 Combination of Immune Checkpoint Inhibitors with Other Drug Classes
  • Table 9.1 Comparison of Marketed Targeted Therapeutics for Melanoma
  • Table 9.2 Comparison of Marketed Targeted Therapeutics for Metastatic NSCLC
  • Table 9.3 Comparison of Marketed Therapeutics for Multiple Myeloma
  • Table 9.4 Comparison of Marketed Therapeutics for Renal Cell Carcinoma
  • Table 10.1 Immune Checkpoint Inhibitors Market: Acquisitions
  • Table 10.2 Immune Checkpoint Inhibitors Market: Co-Development and / or Commercialization Agreements
  • Table 10.3 Immune Checkpoint Inhibitors Market: Product Licensing Agreements
  • Table 10.4 Immune Checkpoint Inhibitors Market: Clinical Trial Collaborations
  • Table 10.5 Immune Checkpoint Inhibitors Market: Contract Manufacturing Agreements
  • Table 10.6 Immune Checkpoint Inhibitors Market: Research Collaborations
  • Table 11.1 List of Funding Rounds / Grants and Investors Involved
  • Table 12.1 BMS: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.2 BMS: Immune Checkpoint Inhibitors Partnerships
  • Table 12.3 Merck: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.4 Merck: Immune Checkpoint Inhibitors Partnerships
  • Table 12.5 AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.6 AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Partnerships
  • Table 12.7 Roche / Genentech: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.8 Roche / Genentech: Immune Checkpoint Inhibitors Partnerships
  • Table 12.9 Pfizer: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.10 Pfizer: Immune Checkpoint Inhibitors Partnerships
  • Table 12.11 Incyte Corporation: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.12 Incyte Corporation: Immune Checkpoint Inhibitors Partnerships
  • Table 12.13 NewLink Genetics: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.14 NewLink Genetics: Immune Checkpoint Inhibitors Partnerships
  • Table 12.15 Innate Pharma: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.16 Innate Pharma: Immune Checkpoint Inhibitors Partnerships
  • Table 12.17 CureTech: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.18 Celldex Therapeutics: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.19 Celldex Therapeutics: Immune Checkpoint Inhibitors Partnerships
  • Table 12.20 arGEN-X: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.21 arGEN-X: Immune Checkpoint Inhibitors Partnerships
  • Table 12.22 Seattle Genetics: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.23 MacroGenics: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.24 GSK: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.25 GITR: Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.26 Agenus Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.27 Agenus: Immune Checkpoint Inhibitors Partnerships
  • Table 12.28 Compugen Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.29 Compugen: Immune Checkpoint Inhibitors Partnerships
  • Table 12.30 Tesaro Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.31 Tesaro: Immune Checkpoint Inhibitors Partnerships
  • Table 12.32 BioNovion Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 12.33 BioNovion: Immune Checkpoint Inhibitors Partnerships
  • Table 12.34 Immutep(Prima Biomed) Immune Checkpoint Inhibitors Pipeline, 2015
  • Table 15.1 Immune Checkpoint Inhibitors: Distribution by Drug Developers
  • Table 15.2 Immune Checkpoint Inhibitors: Distribution by Targets
  • Table 15.3 Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
  • Table 15.4 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Table 15.5 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.6 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.7 Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.8 CTLA-4 Inhibitors: Distribution by Highest Phase of Development
  • Table 15.9 CTLA-4 Inhibitors: Distribution by Type of Molecule
  • Table 15.10 Yervoy Sales, 2011 - 2014(USD Million)
  • Table 15.11 Yervoy /Ipilimumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.12 Yervoy /Ipilimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.13 Yervoy /Ipilimumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.14 Tremelimumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.15 Tremelimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.16 Tremelimumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.17 PD-1 / PD-L1 Inhibitors: Distribution by Drug Developer
  • Table 15.18 PD-1 / PD-L1Inhibitors: Distribution by Target
  • Table 15.19 PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
  • Table 15.20 PD-1 / PD-L1Inhibitors: Distribution by Type of Molecule
  • Table 15.21 Opdivo / Nivolumab Sales, 2014- Q1 2015(USD Million)
  • Table 15.22 Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.23 Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.24 Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.24 Keytruda / Pembrolizumab Sales, 2014-Q1 2015(USD Million)
  • Table 15.25 Keytruda /Pembrolizumab Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.26 Keytruda /Pembrolizumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.27 Keytruda /Pembrolizumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.28 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.29 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.30 MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.31 MEDI4736 Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.32 MEDI4736 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.33 MEDI4736 Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.34 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.35 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.36 Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.37 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
  • Table 15.38 Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
  • Table 15.39 Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
  • Table 15.40 Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Table 15.41 Elotuzumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Table 15.42 Elotuzumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
  • Table 15.43 Elotuzumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
  • Table 15.44 Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
  • Table 15.45 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
  • Table 15.46 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Status of Development
  • Table 15.47 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Immune Checkpoint Inhibitor
  • Table 15.48 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Combination Class
  • Table 15.49 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
  • Table 15.50 Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
  • Table 15.51 Clinical Trial Collaborations: Distribution by Target
  • Table 15.52 Immune Checkpoint Inhibitors Funding Instances: Cumulative Investments by Year, 2001 - 2015
  • Table 15.53 Immune Checkpoint Inhibitors Funding Instances: Distribution by Categories
  • Table 15.54 Immune Checkpoint Inhibitors Funding Instances: Distribution by Amount Invested in a Category (USD Million)
  • Table 15.55 BMS Revenues, 2011 - Q1 2015 (USD Billion)
  • Table 15.56 BMS Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
  • Table 15.57 Merck Revenues, 2009 - Q1 2015 (USD Million)
  • Table 15.58 Merck Revenues: Distribution by Business Segment, 2014 (USD Billion)
  • Table 15.59 AstraZeneca Revenues, 2009 - Q1'2015(USD Million)
  • Table 15.60 AstraZeneca Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
  • Table 15.61 Roche Revenues, 2009 - Q120154 (CHF Billion)
  • Table 15.62 Roche Revenues: Distribution by Business Segments, 2012 - 2014 (CHFBillion)
  • Table 15.63 Roche Pharmaceutical Revenues: Distribution by Therapeutic Areas, 2014 (CHF Billion)
  • Table 15.64 Pfizer Revenues, 2011-Q1 2015 (USD Billion)
  • Table 15.65 Pfizer Revenues: Distribution by Business Segments, 2014 (USD Million)
  • Table 15.66 Pfizer Revenues: Distribution by Therapeutic Areas, 2013 - 2014, (USD '000)
  • Table 15.67 Incyte Corporation Revenues, 2011 - Q12015 (USD Million)
  • Table 15.68 NewLink Genetics Revenues, 2011 - Q1 2015(USD Million)
  • Table 15.69 Innate Pharma Revenues, 2011-Q1 2015(EUR Million)
  • Table 15.70 Celldex Therapeutics Revenues, 2011 - Q1 2015(USD Million)
  • Table 15.71 Seattle Genetics Revenues, 201 - Q1 2015(USD Million)
  • Table 15.72 MacroGenics Revenues, 2011 - Q1 2015(USD Million)
  • Table 15.73 GSK Revenues, 2009 - Q1 2015 (GBP Billion)
  • Table 15.74 GSK Pharmaceutical and Vaccine Revenues: Distribution by Business Domains 2014, (GBP Billion)
  • Table 15.75 Compugen Revenues, 2012 - Q1 2015 (USD Million)
  • Table 15.76 Enumeral Revenues, 2013 - Q1 2015 (USD '000)
  • Table 15.77 Immune Checkpoint Inhibitors Market (USD Billion), 2015, 2020 and 2025

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 4-Antibody
  • 2. 5 AM Ventures
  • 3. Abbott
  • 4. AbbVie
  • 5. Acerta Pharma BV
  • 6. Adimab
  • 7. Advanced Technology Ventures
  • 8. Advaxis
  • 9. Agenus
  • 10. AgonOX
  • 11. Alden Cancer Therapy II
  • 12. Alexandria Real Estate
  • 13. Allen & Company
  • 14. Alligator Bioscience
  • 15. Alloy Ventures
  • 16. Alta Partners
  • 17. Altor Bioscience
  • 18. Ambrx
  • 19. American Cancer Society
  • 20. American Society of Hematology
  • 21. Amgen
  • 22. Amplimmune
  • 23. AnaptysBio
  • 24. Anderson Cancer Center
  • 25. Aravis Ventures
  • 26. Arcus Ventures
  • 27. arGEN-X
  • 28. ARMO BioSciences
  • 29. AstraZeneca
  • 30. Aurigene
  • 31. Avalon Ventures
  • 32. Aventis
  • 33. Azienda Ospedaliera Universitaria Senese
  • 34. Banque Internationale
  • 35. Bayer
  • 36. BeiGene
  • 37. Belgian Walloon Government
  • 38. Belgium and BPI
  • 39. Beth Israel Deaconess Medical Center
  • 40. BioWa
  • 41. Bioceros
  • 42. Biogen Idec New Ventures
  • 43. BioGeneration Ventures
  • 44. BioInvent International AB
  • 45. Bio-Matrix Scientific Group
  • 46. BioNovion
  • 47. Boxer Capital of Tavistock Life Science
  • 48. Brabant Development Agency
  • 49. Brabant Life Sciences Seed Fund
  • 50. Bristol Myers Squibb
  • 51. Caisse de dpt et placement du Qubec
  • 52. California Pacific Medical Center Research Institute
  • 53. Camelot Ventures
  • 54. Cancer Research Institute
  • 55. Casdin Capital
  • 56. Celldex Therapeutics
  • 57. Cellerant Therapeutics
  • 58. Centocor Ortho Biotech
  • 59. Checkpoint Therapeutics
  • 60. Chiron
  • 61. CIDC
  • 62. CITIC Capital Holdings
  • 63. Clal Biotechnology Industries
  • 64. CMEA Capital
  • 65. Cogene BioTech Ventures
  • 66. Cold Genesys
  • 67. Compugen
  • 68. Cormorant Asset Management
  • 69. CoStim Pharmaceuticals
  • 70. Cr&eacutte;dit Agricole Private Equity
  • 71. Curadev
  • 72. CureTech
  • 73. Curis
  • 74. CX Venture Group
  • 75. Dana-Farber Cancer Institute
  • 76. de Duve Institute
  • 77. Deerfield Management and Leerink Swann
  • 78. Dendreon
  • 79. Diamond Capital Company Ltd
  • 80. Domain Associates
  • 81. Dynavax Technologies
  • 82. Eddingpharm
  • 83. Eisai
  • 84. Eli Lilly and Company
  • 85. EMD Serono
  • 86. Emerging Technology Partners
  • 87. Eminent Venture Capital Corp
  • 88. Endocyte
  • 89. Enumeral Biomedical Holdings
  • 90. Erasmus MC Biomedical Fund
  • 91. ESCO Congress
  • 92. Ethe Erasmus Biomedical Fund
  • 93. European Regional Development Fund
  • 94. European Society for Medical Oncology
  • 95. Evogene
  • 96. Facet Biotech
  • 97. Fidelity Management & Research
  • 98. Five Prime Therapeutics
  • 99. Flexus Bioscience
  • 100. Forbion Capital Partners
  • 101. Foresite Capital
  • 102. Frazier Healthcare Partners
  • 103. Fred Hutchinson Cancer Research Center
  • 104. Genentech
  • 105. Genmab
  • 106. Genzyme
  • 107. George Rathmann
  • 108. Gilead
  • 109. GITR Inc.
  • 110. GlaxoSmithKline
  • 111. Grupo Español Multidisciplinar de Melanoma
  • 112. H. Lee Moffitt Cancer Center and Research Institute
  • 113. Hadasit Bio Holdings
  • 114. Harris & Harris Group
  • 115. Harvard University
  • 116. Healthcap Venture Capital
  • 117. HealthCare Ventures
  • 118. Heat Biologics
  • 119. Hillhouse Capital Group
  • 120. Hoffmann-La Roche
  • 121. Home Capital AS
  • 122. Hoosier Cancer Research Network
  • 123. Hunt Ventures
  • 124. Hunza Ventures SCA
  • 125. Imclone
  • 126. ImmuNext
  • 127. Immunocore
  • 128. ImmuTep
  • 129. Incyte Corporation
  • 130. Innate Pharma
  • 131. Innovis Investments
  • 132. Inserm Transfert Initiative
  • 133. Institut Bergoni&eacutte;
  • 134. Institute for the Promotion of Innovation by Science and Technology in Flanders
  • 135. InterWest Partners
  • 136. IOmet Pharma
  • 137. iTeos Therapeutics
  • 138. Janssen Biotech
  • 139. Johns Hopkins University
  • 140. Jonsson Comprehensive Cancer Center
  • 141. Jounce Therapeutics
  • 142. Juno Therapeutics
  • 143. Kadmon Corporation
  • 144. KAHR Medical
  • 145. KBC Securities
  • 146. Keddem Bioscience
  • 147. Kleiner Perkins Caufield & Byers
  • 148. Kyowa Hakko Kirin
  • 149. Laureate Pharma
  • 150. Lee's Pharmaceutical
  • 151. Ludwig Cancer Research
  • 152. Life Sciences Partners
  • 153. Lonza Biologics
  • 154. Ludwig Institute for Cancer Research
  • 155. M.D. Anderson Cancer Center
  • 156. MacroGenics
  • 157. Malmsten Invest
  • 158. Mark Tompkins Montrose Capital
  • 159. Masonic Cancer Center
  • 160. Massachusetts Institute of Technology
  • 161. Maverick Capital
  • 162. Medarex
  • 163. Medicare
  • 164. MedImmune
  • 165. Medivation
  • 166. Melanoma Institute, Australia
  • 167. Memorial Sloan Kettering Cancer Center
  • 168. Merck & Co
  • 169. Merck KGaA
  • 170. Merck Serono Ventures
  • 171. Mithra Ventures
  • 172. Mitsubishi UFJ
  • 173. MorphoSys
  • 174. Morphotek
  • 175. MPM Capital
  • 176. Multimeric Biotherapeutics
  • 177. NantWorks
  • 178. National Cancer Institute
  • 179. National Institutes of Health
  • 180. Nativis
  • 181. NCIC Clinical Trials Group
  • 182. Neviah Genomics
  • 183. New Enterprise Associates
  • 184. New York University School of Medicine
  • 185. NewLink Genetics
  • 186. Nextech Venture
  • 187. Nordic Venture Capital Investor Sunstone Capital
  • 188. Northwest Regional Development Agency
  • 189. Novartis
  • 190. Novel Bioventures
  • 191. Novo Nordisk
  • 192. Numenor Ventures
  • 193. Octalfa
  • 194. Ohio State University Comprehensive Cancer Center
  • 195. Omega Funds
  • 196. Oncothyreon
  • 197. Ono Pharmaceuticals
  • 198. Onyx Pharmaceuticals
  • 199. OPKO Health
  • 200. Oracle Partners
  • 201. OrbiMed
  • 202. Orega Biotech
  • 203. Organon
  • 204. Orphan Medical
  • 205. Pappas Ventures
  • 206. PDL Biopharma
  • 207. Pelican Therapeutics
  • 208. Pfizer
  • 209. Pharmacyclics
  • 210. Pharmstandard
  • 211. Pieris Pharmaceuticals
  • 212. Pierre Fabre
  • 213. Plexxikon
  • 214. Prima BioMed
  • 215. Prometheus Laboratories
  • 216. Providence Health & Services
  • 217. Ragon Institute of Massachusetts General Hospital
  • 218. Recipharm
  • 219. Red Abbey Venture Partners
  • 220. Redmile Group
  • 221. Redx Pharma
  • 222. Regis Technologies
  • 223. Rhône-Alpes Cr&eacutte;ation
  • 224. RiverVest Venture Partners
  • 225. Rock Springs Capital
  • 226. Roswell Park Cancer Institute
  • 227. Samsung Biologics
  • 228. Sanofi
  • 229. Schering Plough Brinny Co.
  • 230. Scottish Venture Fund
  • 231. Seattle Genetics
  • 232. Sequoia Capital
  • 233. Servier
  • 234. Seventure Partners
  • 235. SHAM
  • 236. Sharp & Dohme Corp.
  • 237. Sidney Kimmel Comprehensive Cancer Center
  • 238. Singapore BioInnovations
  • 239. Society of Melanoma Research International Congress
  • 240. Sorrento Therapeutics
  • 241. Southwest Oncology Group
  • 242. Spring Bioscience
  • 243. Syndax Pharmaceuticals
  • 244. Synta Pharmaceuticals
  • 245. Takara Bio Inc.
  • 246. Tavistock Life Sciences
  • 247. Tesaro
  • 248. TetraLogic Pharmaceuticals
  • 249. Texas Pacific Group Ventures
  • 250. TG Therapeutics
  • 251. The Leukemia and Lymphoma Society
  • 252. The University of Texas MD Anderson Cancer Center
  • 253. The Wellcome Trust
  • 254. Theravectys
  • 255. Third Rock Ventures
  • 256. Thomas Jefferson University
  • 257. Thuja Capital Healthcare Funds
  • 258. ToleroTech
  • 259. Tolerx
  • 260. TPG Ventures
  • 261. Transparency Commission
  • 262. Universit&eacutte; Catholique de Louvain
  • 263. United Therapeutics
  • 264. University Hospital Southampton NHS Foundation Trust
  • 265. University of California, Davis
  • 266. University of Iowa Pharmaceutical Services
  • 267. University of Minnesota
  • 268. University of Pittsburgh
  • 269. University of Texas
  • 270. University of Utah
  • 271. Ventana Medical Systems
  • 272. Ventures West
  • 273. Versant Ventures
  • 274. Vlaams Instituut voor Biotechnologie
  • 275. Vinnova
  • 276. Viralytics
  • 277. VIVES Louvain Technology Fund
  • 278. Vivo Ventures
  • 279. VLST Corporation
  • 280. Walloon
  • 281. Washington University School of Medicine
  • 282. Wellcome Trust Sanger Institute
  • 283. Wellington Management
  • 284. WS Investments
  • 285. Wyeth
Back to Top